PIA
NMTR

Piedmont Investment Advisors’s 9 Meters Biopharma NMTR Stock Holding History

Piedmont Investment Advisors’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16
Closed -$8K – 2488
2018
Q2 		$8K Buy
+16
New +$5.89K ﹤0.01% 1941

Other funds holding NMTR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Piedmont Investment Advisors's NMTR Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of 9 Meters Biopharma (NMTR) in Q3 2018, closing a stake of 16 shares — an estimated $8K sold.

Piedmont Investment Advisors first reported a position in NMTR in Q2 2018 and held it in 1 quarter. The position peaked at $8K in Q2 2018. 45 funds tracked by Wall St. Rank hold NMTR as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining 9 Meters Biopharma position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 16 9 Meters Biopharma shares in Q3 2018, an estimated $8K.
  • Piedmont Investment Advisors first reported a position in 9 Meters Biopharma in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's 9 Meters Biopharma position peaked at $8K in Q2 2018.
  • 45 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.